This written statement and oral statements or other statements made, or to be made, by us contain forward-looking statements that do not relate solely to historical or current facts. These forward-looking statements are based on the current plans and expectations of our management and are subject to a number of uncertainties and risks that could significantly affect our current plans and expectations, as well as future results of operations and financial condition. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Half Year Results 2023
2
Agenda
Media and financial analysts conference call H1 2023
Highlights H1 2023
Martin Schaufelberger, CEO
Financials H1 2023 Markus Abderhalden, CFO
Outlook
Martin Schaufelberger, CEO
Q&A All
Half Year Results 2023
3
Highlights H1 2023
Record free cash flow and strong balance sheet basis for further growth
Key figures • Net sales CHF 131.4 m (PY CHF 134.9 m); +1.7% adjusted by FX and -2.6% in CHF
EBIT margin at 11.0% (PY 12.4%)
Net profit amounted to CHF 10.0 m (PY CHF 12.1 m)
Free Cash Flow at CHF 16.7 m (PY CHF 7.8 m)
Operational • Backlog situation of devices in Infection Control mostly solved
Delays by the notified body caused negative impact on Endo business
Due to strict cost management, operating costs were reduced by 4.7%
COLTENE is well prepared for the new European Medical Device Regulation (MDR) and meets already the high product and process quality requirement for most of its business
Increasing patient safety thanks to the new traceability system of the reprocessing of instruments based on the digital platform my.coltene
Implementation of non-financial reporting requirements and projects for reduction of CO2 emission
Organizational • Gregor Picard started as new COO as per 1st April replacing Stefan Helsing due to retirement
Half Year Results 2023
4
Net Sales by Product Groups
Strong development of Infection Control due to the clearing of backlogs
Net Sales H1 2023 by product groups (shares)
Dental Preservation
(HY1 2022: 30.4%)
Infection Control
28.2%
(HY1 2022: 31.2%)
34.0%
37.8%
Efficient Treatment (HY1 2022: 38.4%)
Net Sales by product groups (in CHF m)
52
+6.2%
-
4.2%
52
50
50
-
9.5%
45
42
41
41
37
2021 2022
2023
Infection Control
Efficient
Dental
Treatment
Preservation
Half Year Results 2023
5
Attachments
Original Link
Original Document
Permalink
Disclaimer
Coltene Holding AG published this content on 04 August 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 August 2023 04:43:03 UTC.
Coltene Holding AG is a Switzerland-based Company active in the healthcare sector. It develops, manufactures and sells dental consumables and small equipment focusing on mechanical instruments and filling materials. It has production facilities in Switzerland, the United States, Germany and Hungary. The Company's product range comprises six product groups: Adhesives / Restoratives; Endodontics; Prosthetics; Rotary Instruments; Treatment Auxiliaries; and Hygiene. Coltene Holding AG has a number of wholly owned subsidiaries active in production and sales of dental specialties based in Switzerland, Germany, Hungary, Canada, the United Kingdom, France, China, India, the United States and Brazil.
COLTENE HOLDING AG 
